Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia (Globe Newswire)
UF Innovate | Accelerate graduate Oragenics has received final ethics approval in Australia to begin its Phase IIa clinical trial of ONP-002, an intranasal therapy being developed to treat concussion and mild traumatic brain injury.